These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 2194531)

  • 1. Current status of epirubicin (Farmorubicin) in the treatment of solid tumours.
    Mouridsen HT; Alfthan C; Bastholt L; Bergh J; Dalmark M; Eksborg S; Hellsten S; Kjaer M; Peterson C; Skovsgård T
    Acta Oncol; 1990; 29(3):257-85. PubMed ID: 2194531
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of dexrazoxane as a cardioprotectant in patients receiving doxorubicin or epirubicin chemotherapy for the treatment of cancer. The Provincial Systemic Treatment Disease Site Group.
    Seymour L; Bramwell V; Moran LA
    Cancer Prev Control; 1999 Apr; 3(2):145-59. PubMed ID: 10474762
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epirubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cancer chemotherapy.
    Plosker GL; Faulds D
    Drugs; 1993 May; 45(5):788-856. PubMed ID: 7686469
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epirubicin. Clinical pharmacology and dose-effect relationship.
    Robert J
    Drugs; 1993; 45 Suppl 2():20-30. PubMed ID: 7693418
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Paclitaxel and epirubicin as first-line therapy for patients with metastatic breast cancer.
    Lück HJ; Du Bois A; Thomssen C; Lisboa B; Untch M; Köhler G; Hecker D
    Oncology (Williston Park); 1997 Apr; 11(4 Suppl 3):34-7. PubMed ID: 9144689
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epirubicin cardiotoxicity: a study comparing low- with high-dose-intensity weekly schedules.
    Berchem GJ; Ries F; Hanfelt J; Duhem C; Keipes M; Delagardelle C; Dicato M
    Support Care Cancer; 1996 Jul; 4(4):308-12. PubMed ID: 8829311
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Comparison of the cytotoxic activity of doxorubicin and epirubicin by an in vitro test].
    Czownicki Z; Rosińska U; Kilka C
    Pol Arch Med Wewn; 1989; 82(2-3):71-6. PubMed ID: 2638740
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics and toxicity of two schedules of high dose epirubicin.
    Tjuljandin SA; Doig RG; Sobol MM; Watson DM; Sheridan WP; Morstyn G; Mihaly G; Green MD
    Cancer Res; 1990 Aug; 50(16):5095-101. PubMed ID: 2379173
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical pharmacokinetics of epirubicin.
    Robert J
    Clin Pharmacokinet; 1994 Jun; 26(6):428-38. PubMed ID: 8070217
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Contradistinction between doxorubicin and epirubicin: in-vitro interaction with blood components.
    Ramanathan-Girish S; Boroujerdi M
    J Pharm Pharmacol; 2001 Jun; 53(6):815-21. PubMed ID: 11428657
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epirubicin: is it like doxorubicin in breast cancer? A clinical review.
    Khasraw M; Bell R; Dang C
    Breast; 2012 Apr; 21(2):142-9. PubMed ID: 22260846
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comparative study of doxorubicin and epirubicin in patients with metastatic breast cancer.
    Hortobagyi GN; Yap HY; Kau SW; Fraschini G; Ewer MS; Chawla SP; Benjamin RS
    Am J Clin Oncol; 1989 Feb; 12(1):57-62. PubMed ID: 2643296
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epirubicin. An updated review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of breast cancer.
    Coukell AJ; Faulds D
    Drugs; 1997 Mar; 53(3):453-82. PubMed ID: 9074845
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Continuous infusion of low-dose doxorubicin, epirubicin and mitoxantrone in cancer chemotherapy: a review.
    Greidanus J; Willemse PH; Uges DR; Oremus ET; De Langen ZJ; De Vries EG
    Pharm Weekbl Sci; 1988 Dec; 10(6):237-45. PubMed ID: 3062572
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative study of the pharmacokinetics and toxicity of high-dose epirubicin with or without dexrazoxane in patients with advanced malignancy.
    Basser RL; Sobol MM; Duggan G; Cebon J; Rosenthal MA; Mihaly G; Green MD
    J Clin Oncol; 1994 Aug; 12(8):1659-66. PubMed ID: 8040678
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A prospective randomized phase III trial comparing combination chemotherapy with cyclophosphamide, fluorouracil, and either doxorubicin or epirubicin. French Epirubicin Study Group.
    J Clin Oncol; 1988 Apr; 6(4):679-88. PubMed ID: 2895801
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epirubicin in combination with the taxanes.
    Trudeau M; Pagani O
    Semin Oncol; 2001 Aug; 28(4 Suppl 12):41-50. PubMed ID: 11552229
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epirubicin: a review of its efficacy as adjuvant therapy and in the treatment of metastatic disease in breast cancer.
    Ormrod D; Holm K; Goa K; Spencer C
    Drugs Aging; 1999 Nov; 15(5):389-416. PubMed ID: 10600046
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase I clinical and pharmacokinetic study evaluating vinflunine in combination with epirubicin as first-line treatment in metastatic breast cancer.
    Chan S; Campone M; Santoro A; Conte PF; Bostnavaron M; Nguyen L
    Cancer Chemother Pharmacol; 2014 May; 73(5):903-10. PubMed ID: 24627219
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dose escalation study of epirubicin and docetaxel in patients with advanced or recurrent breast cancer.
    Ichinose I; Hamada Y; Mitsuyama S; Ishikawa E; Ikeda T; Kobayashi S; Horikoshi N; Tamura K
    Chemotherapy; 2008; 54(5):379-85. PubMed ID: 18758179
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.